CN101274921A - 一种牛磺罗定的合成方法及药物制剂 - Google Patents
一种牛磺罗定的合成方法及药物制剂 Download PDFInfo
- Publication number
- CN101274921A CN101274921A CNA2008100506624A CN200810050662A CN101274921A CN 101274921 A CN101274921 A CN 101274921A CN A2008100506624 A CNA2008100506624 A CN A2008100506624A CN 200810050662 A CN200810050662 A CN 200810050662A CN 101274921 A CN101274921 A CN 101274921A
- Authority
- CN
- China
- Prior art keywords
- taurolidine
- reaction
- tauryl
- preparation
- reaction solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- AJKIRUJIDFJUKJ-UHFFFAOYSA-N taurolidine Chemical compound C1NS(=O)(=O)CCN1CN1CNS(=O)(=O)CC1 AJKIRUJIDFJUKJ-UHFFFAOYSA-N 0.000 title claims abstract description 31
- 229960004267 taurolidine Drugs 0.000 title claims abstract description 31
- 238000010189 synthetic method Methods 0.000 title claims abstract description 6
- 239000000825 pharmaceutical preparation Substances 0.000 title description 4
- 238000006243 chemical reaction Methods 0.000 claims abstract description 30
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims abstract description 18
- 238000002360 preparation method Methods 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 12
- 238000003756 stirring Methods 0.000 claims description 19
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 15
- -1 tauryl azide salt Chemical class 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000007787 solid Substances 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 6
- 239000000460 chlorine Substances 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 239000007789 gas Substances 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 6
- 239000005457 ice water Substances 0.000 claims description 6
- 238000000967 suction filtration Methods 0.000 claims description 6
- 125000003666 tauryl group Chemical group [H]N([H])C([H])([H])C([H])([H])S(*)(=O)=O 0.000 claims description 6
- 238000001291 vacuum drying Methods 0.000 claims description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims description 4
- 238000005984 hydrogenation reaction Methods 0.000 claims description 4
- 229960003151 mercaptamine Drugs 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 3
- 230000008030 elimination Effects 0.000 claims description 3
- 238000003379 elimination reaction Methods 0.000 claims description 3
- 239000012065 filter cake Substances 0.000 claims description 3
- 239000008098 formaldehyde solution Substances 0.000 claims description 3
- 238000010907 mechanical stirring Methods 0.000 claims description 3
- 229910000474 mercury oxide Inorganic materials 0.000 claims description 3
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical compound [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 claims description 3
- 230000005311 nuclear magnetism Effects 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 239000000376 reactant Substances 0.000 claims description 3
- 230000009466 transformation Effects 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims 1
- 239000012266 salt solution Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 150000001540 azides Chemical class 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- OGMADIBCHLQMIP-UHFFFAOYSA-N 2-aminoethanethiol;hydron;chloride Chemical compound Cl.NCCS OGMADIBCHLQMIP-UHFFFAOYSA-N 0.000 abstract 1
- 238000006482 condensation reaction Methods 0.000 abstract 1
- 229940097265 cysteamine hydrochloride Drugs 0.000 abstract 1
- 230000035876 healing Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000000843 powder Substances 0.000 description 6
- 239000003978 infusion fluid Substances 0.000 description 5
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 208000037815 bloodstream infection Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- KMOUUZVZFBCRAM-OLQVQODUSA-N (3as,7ar)-3a,4,7,7a-tetrahydro-2-benzofuran-1,3-dione Chemical compound C1C=CC[C@@H]2C(=O)OC(=O)[C@@H]21 KMOUUZVZFBCRAM-OLQVQODUSA-N 0.000 description 1
- DHPRQBPJLMKORJ-XRNKAMNCSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O DHPRQBPJLMKORJ-XRNKAMNCSA-N 0.000 description 1
- OQUFOZNPBIIJTN-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;sodium Chemical compound [Na].OC(=O)CC(O)(C(O)=O)CC(O)=O OQUFOZNPBIIJTN-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 206010014568 Empyema Diseases 0.000 description 1
- 206010031149 Osteitis Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001986 anti-endotoxic effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 208000018339 bone inflammation disease Diseases 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Images
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100506624A CN101274921B (zh) | 2008-04-28 | 2008-04-28 | 一种牛磺罗定的合成方法及药物制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100506624A CN101274921B (zh) | 2008-04-28 | 2008-04-28 | 一种牛磺罗定的合成方法及药物制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101274921A true CN101274921A (zh) | 2008-10-01 |
CN101274921B CN101274921B (zh) | 2010-06-02 |
Family
ID=39994818
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008100506624A Active CN101274921B (zh) | 2008-04-28 | 2008-04-28 | 一种牛磺罗定的合成方法及药物制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101274921B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106748905A (zh) * | 2016-12-14 | 2017-05-31 | 河南省化工研究所有限责任公司 | 一种制备2‑氨基乙基磺酰胺盐酸盐的方法 |
CN107586267A (zh) * | 2016-11-01 | 2018-01-16 | 华东师范大学 | 一种牛磺酰胺盐酸盐(2‑氨基乙基磺酰胺盐酸盐)的合成方法 |
CN111617086A (zh) * | 2020-07-06 | 2020-09-04 | 长春迈灵生物工程有限公司 | 牛磺罗定在制备抗hpv病毒药物中的应用 |
CN114539106A (zh) * | 2022-03-15 | 2022-05-27 | 梯尔希(南京)药物研发有限公司 | 一种稳定同位素标记的牛磺酰胺盐酸盐的合成方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060104968A1 (en) * | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
US20060073173A1 (en) * | 2004-10-04 | 2006-04-06 | Maria Banach | Large-scale manufacturing process for the production of pharmaceutical compositions |
EP1647276A1 (en) * | 2004-10-14 | 2006-04-19 | Boehringer Ingelheim Vetmedica Gmbh | Use of taurolidine formulations for the intramammary treatment of mastitis |
DE102005017845A1 (de) * | 2005-04-18 | 2006-10-19 | Lohmann & Rauscher Gmbh & Co. Kg | Autosterile, antiseptische Kollagenzubereitungen, ihre Verwendung und Verfahren zu ihrer Herstellung |
-
2008
- 2008-04-28 CN CN2008100506624A patent/CN101274921B/zh active Active
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107586267A (zh) * | 2016-11-01 | 2018-01-16 | 华东师范大学 | 一种牛磺酰胺盐酸盐(2‑氨基乙基磺酰胺盐酸盐)的合成方法 |
CN107586267B (zh) * | 2016-11-01 | 2020-02-18 | 华东师范大学 | 一种牛磺酰胺盐酸盐(2-氨基乙基磺酰胺盐酸盐)的合成方法 |
CN106748905A (zh) * | 2016-12-14 | 2017-05-31 | 河南省化工研究所有限责任公司 | 一种制备2‑氨基乙基磺酰胺盐酸盐的方法 |
CN111617086A (zh) * | 2020-07-06 | 2020-09-04 | 长春迈灵生物工程有限公司 | 牛磺罗定在制备抗hpv病毒药物中的应用 |
CN114539106A (zh) * | 2022-03-15 | 2022-05-27 | 梯尔希(南京)药物研发有限公司 | 一种稳定同位素标记的牛磺酰胺盐酸盐的合成方法 |
CN114539106B (zh) * | 2022-03-15 | 2023-05-02 | 梯尔希(南京)药物研发有限公司 | 一种稳定同位素标记的牛磺酰胺盐酸盐的合成方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101274921B (zh) | 2010-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101365439B (zh) | 左旋多巴前体药物甲磺酸盐、其组合物及其用途 | |
CN102351842B (zh) | 甲磺酸伊马替尼的f、g、h、i 和k晶形 | |
CN101068533B (zh) | 含有抗成核剂的药物组合物 | |
CN102295635B (zh) | 抗肿瘤药物四氢化萘酰胺类化合物及其药学上可接受的盐及制备方法和应用 | |
CN104053442A (zh) | 某些化学实体、组合物及方法 | |
CN110627755B (zh) | 一种γ-丁内酯二聚体抗癌化合物及其制备方法 | |
EP2776405A1 (en) | 2-thiopyrimidinones | |
CN101274921B (zh) | 一种牛磺罗定的合成方法及药物制剂 | |
CN102603743A (zh) | 抗肿瘤的氮杂苯并[f]薁衍生物其制备方法及其用途 | |
CN112010839B (zh) | 靶向丝/苏氨酸激酶抑制剂的晶型 | |
US6730689B2 (en) | N-[4-(1H-imidazol-1-yl)-2-fluorophenyl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamides as factor Xa inhibitors | |
CN104230912B (zh) | 喹啉衍生物、其制备方法及其用途 | |
JP6275644B2 (ja) | N−[2−({2−[(2S)−2−シアノピロリジン−1−イル]−2−オキソエチル}アミノ)−2−メチルプロピル]−2−メチルピラゾロ[1,5−a]ピリミジン−6−カルボキサミドの結晶 | |
KR20140123081A (ko) | 아미노산과 카르복실산을 포함한 게르마늄의 착체 및 이를 제조하는 방법 | |
CN106518933A (zh) | 二茂铁衍生物及其制备方法和用途 | |
CN102911177B (zh) | 7-(4-氯苯基)-5,6-二氢-7aH-苯并[h]1,2,4-三氮唑并[3,4-b]喹唑啉-5,6-二酮及其合成方法 | |
CN102060792B (zh) | 2′-胺基查尔酮唑类化合物及其吡唑啉和环丙基唑类衍生物、制备方法与用途 | |
CN105348187B (zh) | 一种贝曲西班结构类似物及其制备方法和用途 | |
HU230034B1 (hu) | Acetil-L-karnitin szerves dikarbonsavval alkotott sója és eljárás előállítására | |
CN101787029A (zh) | 长链烷基黄连碱卤酸盐衍生物、合成方法及用途 | |
CN104926804A (zh) | 一类具有抗肿瘤作用的化合物、其制备方法和用途 | |
CN116854675A (zh) | 一种含香豆素与硫脲嘧啶的酯类衍生物及其制备方法和应用 | |
CN108752404A (zh) | 一种三氮唑糖修饰的小檗碱盐衍生物及其制备方法和用途 | |
CN114516870B (zh) | 一种三唑并六元氮杂环-3-胺类化合物及其制备方法和应用 | |
CN115010642B (zh) | β-榄香烯酰亚胺类衍生物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: CHANGCHUN SANZHEN INDUSTRY CO., LTD. Free format text: FORMER OWNER: CHANGCHUN MAILING BIOENGINEERING CO., LTD. Effective date: 20100527 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 130021 3/F, BUILDING C, NANBO BUILDING, NO.7043, RENMIN STREET, CHANGCHUN CITY, JILIN PROVINCE TO: 130022 3/F, BLOCK C, NANBO BUILDING, NO.7043, RENMIN STREET, CHANGCHUN CITY |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20100527 Address after: 130022 Changchun Renmin Street, No. 7043 South Building C block 3 layer Applicant after: Sanzhen Industrial Co., Ltd., Changchun Address before: The people of 130021 cities in Jilin province Changchun Street No. 7043 South Building C block three layer Applicant before: Changhun Mailing Biotechnology Co., Ltd. |
|
CB03 | Change of inventor or designer information |
Inventor after: Zhang Baofu Inventor after: Li Yingtie Inventor after: Wu Jie Inventor after: Du Hongming Inventor after: Gao Qiang Inventor after: Su Zhong Inventor before: Zhang Baofu Inventor before: Li Yingtie Inventor before: Wu Jie Inventor before: Du Hongming Inventor before: Gao Qiang Inventor before: Su Zhong |
|
CB03 | Change of inventor or designer information | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190404 Address after: 130000 3 storeys, Block C, Nanbo Building, 7043 Renmin Street, Chaoyang District, Changchun City, Jilin Province Patentee after: Changhun Mailing Biotechnology Co., Ltd. Address before: 3 floor, block C, Nan Po building, 7043 people's street, Changchun. Patentee before: Sanzhen Industrial Co., Ltd., Changchun |
|
TR01 | Transfer of patent right |